Federated Hermes
DNTH icon

Federated Hermes’s Dianthus Therapeutics DNTH Stock Holding History

Federated Hermes’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,832
Closed -$227K – 2160
2022
Q2 		$227K Sell
11,832
-12,380
-51% -$306K ﹤0.01% 1514
2022
Q1 		$1.12M Buy
24,212
+8,392
+53% +$458K ﹤0.01% 1204
2021
Q4 		$1.12M Buy
15,820
+2,273
+17% +$228K ﹤0.01% 1233
2021
Q3 		$1.58M Sell
13,547
-52
-0.4% -$6.06K ﹤0.01% 1117
2021
Q2 		$2.13M Buy
13,599
+7,268
+115% +$1.34M ﹤0.01% 1076
2021
Q1 		$1.2M Buy
6,331
+6,038
+2,061% +$1.02M ﹤0.01% 1303
2020
Q4 		$37K Buy
293
+26
+10% +$2.95K ﹤0.01% 1848
2020
Q3 		$29K Hold
267
– – ﹤0.01% 1851
2020
Q2 		$32K Sell
267
-16
-6% -$2.25K ﹤0.01% 1815
2020
Q1 		$28K Sell
283
-14
-5% -$2.59K ﹤0.01% 1753
2019
Q4 		$72K Sell
297
-68
-19% -$12.7K ﹤0.01% 1707
2019
Q3 		$60K Buy
365
+133
+57% +$25.3K ﹤0.01% 1704
2019
Q2 		$55K Buy
+232
New +$57.4K ﹤0.01% 1663

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Federated Hermes's DNTH Position: Q3 2022 in Review

Federated Hermes sold out of Dianthus Therapeutics (DNTH) in Q3 2022, closing a stake of 11,832 shares — an estimated $227K sold.

Federated Hermes first reported a position in DNTH in Q2 2019 and held it in 13 quarters. The position peaked at $2.13M in Q2 2021. 72 funds tracked by Wall St. Rank hold DNTH as of Q3 2022.

  • Federated Hermes reported no remaining Dianthus Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Federated Hermes sold 11,832 Dianthus Therapeutics shares in Q3 2022, an estimated $227K.
  • Federated Hermes first reported a position in Dianthus Therapeutics in Q2 2019 and held it in 13 quarters.
  • Federated Hermes's Dianthus Therapeutics position peaked at $2.13M in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2022.

Based on Federated Hermes's 13F filing for Q3 2022, filed 14 Nov 2022.